|
March
29, 2007--The U.S. Food and Drug Administration (FDA)
announced that Pergolide drug products, which are used to treat
Parkinson’s disease, are being voluntarily withdrawn
because of the risk of serious damage to patients’ heart
valves. The
products involved are Valeant Pharmaceuticals’ Permax
and two generic versions of pergolide manufactured by Par
and Teva. Pergolide is in a class of medications called
dopamine agonists, which are used with levodopa and
carbidopa to manage the symptoms (tremors and slowness of
movement) of Parkinson’s disease.
For
more information see FDA
Press Release.
|
